This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mortensen, L. Articles by Johnston, C. C. Search for Related Content PubMed PubMed Citation Articles by Mortensen, L. Articles by Johnston, C. C., Jr.

Risedronate Increases Bone Mass in an Early Postmenopausal Population: Two Years of Treatment Plus One Year of Follow-Up¹

University Department of Endocrinology and Metabolism (L.M., P.C.), Aarhus Amtssygehus, Aarhus, Denmark; Procter & Gamble Pharmaceuticals (P.J.B., J.D.), Cincinnati, Ohio 45242; Indiana University School of Medicine (C.C.J.), Indianapolis, Indiana 46202.

Address correspondence and requests for reprints to: Lene Mortensen, MD, PhD, University Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Tage Hansensgade 2, DK-8000, Aarhus C, Denmark.

This double-blind, placebo-controlled study was undertaken to determine 1)the efficacy of oral risedronate for prevention of bone loss in healthy, early postmenopausal patients with normal bone mass, 2)the effect on bone mass when treatment was stopped, and 3)the safety and tolerance of risedronate in this population. A group of 111 patients were randomized to oral placebo, risedronate 5 mg daily, or risedronate 5 mg cyclically, for 2 yr followed by 1 yr off treatment. Measurements included percentage change from baseline in lumbar spine bone mineral density (BMD) at 24 months; percentage change from baseline in BMD of the femoral neck, trochanteric region, and Ward’s triangle region of the proximal femur; and changes in biochemical markers of bone turnover. After 2 yr, there was a mean increase in BMD of the lumbar spine of 1.4% from baseline and of 5.7% vs. placebo in the risedronate 5 mg daily group. There were decreases from baseline in BMD of 1.6% and 4.3% in the risedronate 5 mg cyclic and placebo groups, respectively. By the end of 24 months, trochanteric bone mass at the hip increased by 5.4% in the risedronate 5 mg daily group and by 3.3% in the risedronate 5 mg cyclic group vs. placebo. Bone mass was maintained at the femoral neck in the 2 active-treatment groups vs. a 2.4% mean loss with placebo. During the treatment-free follow-up, bone turnover increased toward baseline in both risedronate groups. By the end of that year, lumbar spine bone mass in all 3 groups was lower than at baseline. Oral risedronate was well tolerated. We conclude that risedronate (5 mg daily) increases bone mass and risedronate (5 mg cyclic) appears to prevent bone loss in early postmenopausal women with normal BMD.

This article has been cited by other articles:

				P. F. Cook, S. Emiliozzi, and M. M. McCabe Telephone Counseling to Improve Osteoporosis Treatment Adherence: An Effectiveness Study in Community Practice Settings American Journal of Medical Quality, December 1, 2007; 22(6): 445 - 456. [Abstract] [PDF]

				M. R. McClung Bisphosphonate Therapy: To Stop or Not to Stop? IBMS BoneKEy, February 1, 2007; 4(2): 78 - 82. [Full Text] [PDF]

				S. Jehle, A. Zanetti, J. Muser, H. N. Hulter, and R. Krapf Partial Neutralization of the Acidogenic Western Diet with Potassium Citrate Increases Bone Mass in Postmenopausal Women with Osteopenia J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3213 - 3222. [Abstract] [Full Text] [PDF]

				J A Stakkestad, L I Benevolenskaya, J J Stepan, A Skag, A Nordby, E Oefjord, A Burdeska, I Jonkanski, and P Mahoney Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women Ann Rheum Dis, October 1, 2003; 62(10): 969 - 975. [Abstract] [Full Text]

				A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, A. Papaioannou, V. Robinson, B. Shea, G. Wells, and G. Guyatt III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis Endocr. Rev., August 1, 2002; 23(4): 517 - 523. [Full Text] [PDF]

				J. C. Gallagher, D. J. Baylink, R. Freeman, and M. McClung Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4717 - 4726. [Abstract] [Full Text] [PDF]

				C. Crandall Risedronate: A Clinical Review Arch Intern Med, February 12, 2001; 161(3): 353 - 360. [Abstract] [Full Text] [PDF]

				I. Fogelman and G. M. Blake Different Approaches to Bone Densitometry J. Nucl. Med., December 1, 2000; 41(12): 2015 - 2025. [Abstract] [Full Text] [PDF]

				I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, and J.-Y. Reginster Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1895 - 1900. [Abstract] [Full Text]

				P. Ravn, S. R. Weiss, J. A. Rodriguez-Portales, M. R. McClung, R. D. Wasnich, N. L. Gilchrist, P. Sambrook, I. Fogelman, D. Krupa, A. J. Yates, et al. Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1492 - 1497. [Abstract] [Full Text]

				A. A. Reszka, J. M. Halasy-Nagy, P. J. Masarachia, and G. A. Rodan Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis. A LINK BETWEEN INHIBITION OF THE MEVALONATE PATHWAY AND REGULATION OF AN APOPTOSIS-PROMOTING KINASE J. Biol. Chem., December 3, 1999; 274(49): 34967 - 34973. [Abstract] [Full Text] [PDF]

				S. T. Harris, N. B. Watts, H. K. Genant, C. D. McKeever, T. Hangartner, M. Keller, C. H. Chesnut III, J. Brown, E. F. Eriksen, M. S. Hoseyni, et al. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial JAMA, October 13, 1999; 282(14): 1344 - 1352. [Abstract] [Full Text] [PDF]